| abstract |
A novel antitumour composition including a cell population capable of expressing at least three therapeutic genes, particularly immunostimulatory and/or cytotoxic genes, is disclosed. A packaging cell expressing interleukin-2 and a retroviral vector expressing the gamma-interferon and thymidine kinase genes of herpes simplex virus 1 (HSV-1), as well as the therapeutical use thereof for preventing and treating cancer, are also disclosed. |